About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

RECRUITINGPhase 2

Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JYP0015 in Advanced Solid Tumors With RAS Mutation

NCT06895031•Guangzhou JOYO Pharma Co., Ltd

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Solid TumorPancreatic Ductal Adenocarcinoma (PDAC)Non-small Cell Lung Cancer (NSCLC)+1 more

Interventions

JYP0015

Locations

1

China

Locations (1)

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

March 31, 2025

Primary Completion Date

March 30, 2026

Completion Date

December 31, 2026

Last Updated

March 6, 2026

Related Studies

RECRUITINGPhase 1

Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors

NCT06132828

RECRUITINGPhase 2

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

NCT04570423

Solid TumorsLymphoma

RECRUITINGPhase 1/2

GT201 Injection For The Treatment Of Advanced Solid Tumors

NCT06144671

Solid Tumor, Adult

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

NCT07489378

Very Rare TumorsVery Rare Cancers+3 more

RECRUITINGPhase 1

A Study of DXC014 in Patients With Advanced Solid Tumors.

NCT07177937

Small Cell Lung CancerMelanoma+2 more

RECRUITINGPhase 1

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

NCT06926283

Prostate CancerOther Solid Tumors+1 more

View all related studies

Contacts

Ling Shen, M.D.

CONTACT

01088121122 linshenpku@163.com

Xiao

CONTACT

Sponsors

Lead Sponsor

Guangzhou JOYO Pharma Co., Ltd

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2026Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions